On Mar. 25, 1999, Novo Nordisk, the ZymoGenetics parent company announced approval of NovoSeven by the FDA for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to coagulation Factors VIII or IX. Seattle based ZymoGenetics was instrumental in the development of NovoSeven(R) Coagulation Factor VIIa (Recombinant), a lifesaving product.